The objective of this study was to determine whether transfection of human islets with an adenovirus con struct encoding an inhibitor of tumor necrosis factor (TNFi) was effective at limiting damage to beta cells induced by human peripheral blood leukocytes (huPBL). Human islets transfected with TNFi or control islets were transplanted under the kidney capsule of NOD-scid mice. After a 15-day engraftment period, half of the mice received injections of activated huPBL and half received buffer injections. Islet graft function was assessed by two different methods, both of which use a species-specific radioimmunoassay to determine human insulin. In some mice, insulin production following intraperitoneal glucose injection was determined in serum. In other mice, total graft insulin content was determined by acid ethanol extraction. Histochemical stains were performed on some kidneys at the termination of the experiment to evaluate graft presence, transgene expression, and huPBL infiltration. In huPBL injected mice, graft performance was maintained in mice whose grafts were transfected with TNFi but declined substantially in control groups with sham trans fected or p-galactosidase transfected islet grafts. Similar results were obtained using either glucose-stimu lated insulin release or graft insulin content as a measure of graft survival. There was no significant differ ence in graft function between control groups receiving buffer injections, regardless of whether the islets had been transfected. Human leukocytes were found in all huPBL groups regardless of islet transfection status. We conclude that transfection of human islets with an adenovirus encoding TNFi protects beta cells from destruction induced by human leukocytes. The local production of TNFi does not prevent graft infiltra tion by leukocytes, only the destruction of grafts by the infiltrating leukocytes. These results raise the possi bility that local expression of an inhibitor of the proinflammatory cytokine TNF-a may also prevent graft failure in clinical islet transplantation.
INTRODUCTION
Type I diabetes mellitus (DM) is the result of an auto immune destruction of the insulin-producing cells in the islet of Langerhans. Patients are dependent on insulin injection therapy in order to maintain proper blood glu cose levels. Unfortunately, standard therapy fails to completely approximate physiologic glycemia, and in tensive therapy can cause a two-to threefold increase in the number of severe hypoglycemic episodes (15) . As a result, large numbers of patients suffer, and a method of glucose regulation more comparable to normal pancre atic islet function is needed (26) .
A substantial research effort has been focused on al ternatives to insulin injection, especially the pursuit of islet or pancreas transplantation and gene therapy. Suc cessful transplantation of pancreatic islet cells could of fer patients the benefits of metabolic control without the side effects of insulin injection therapy. Unfortunately, islet transplant procedures in humans thus far have yielded minimal success, with the majority of patients unable to stop insulin injections. Improved techniques of cadaver islet recovery, combined with advances in protocols for pretransplant treatment of islet cells and recipients, have generated optimism among islet trans plant researchers. However, severe problems of early graft destruction remain (28) .
In vivo function of human islets can be studied by engrafting them into severe combined immunodeficient (scid) mice. These mice lack mature T and B lympho cytes (5, 8) and thus cannot mount adaptive immune re sponses to reject xenografts of human cells (30) . We have used nonobese diabetic-scid (NOD-scid) mice, which have defects in innate immunity in addition to the scid defects (21, 31) , to study human islet engraftment and in vivo function. Survival and engraftment of human lymphoid tissue is greatly improved in NOD-scid com pared to C.B-17-scid mice (16) . In our model, human graft function is quantitated by measuring the insulin response to glucose injections in fasted mice. Graft func tion remains stable after a short engraftment period, and apparently graft survival is limited only by the viability of the mice themselves (13) . We also found that injec tion of staphylococcal enterotoxin B (SEB)-activated human peripheral blood leukocytes (huPBL) into mice with human islet grafts induces deterioration of graft function (14) .
Based on the findings of several groups, Nerup et al. (24) proposed a cytokine-driven model for autoimmune destruction of beta cells in type I DM. They had pre viously noted that IL-1, potentiated by TNF-a, was cy totoxic to islets (22, 23) . They went on to suggest that before islet invasion by T lymphocytes occurs, macro phage secretion of cytokines (IL-1 and TNF-a) induces a free radical (0 2~ and NO) destruction of beta cells.
Because of the nearly immediate nonfunction of trans planted islets in human patients, a similar cytokineinduced cascade effect, rather than normal adaptive immune-mediated graft rejection processes, could play a major role in islet graft failure (28) . To address this problem, we decided to develop a procedure that would protect human islets against cytokine-induced beta cell destruction.
Advancement in transfection technology has made it possible to achieve long-term production of transgenes in many tissues. Transfer of genes into rodent islets us ing a replication-defective adenoviral vector has been demonstrated (4, 6, 33, 35) . Kolls et al. (20) successfully developed an adenovirus to deliver a chimeric binding protein of tumor necrosis factor (TNFi) and found de tectable levels of TNFi in serum of mice up to 6 weeks after injection (20, 25) . To create a local zone of protec tion against inflammation and cytokine damage, we transfected human islets with the same adenovirus con struct. We then placed the islets in NOD-scid mice to determine whether or not transfection by itself affected graft function. Finally, we injected mice with activated huPBL 14 days after transplantation to evaluate whether local production of TNFi could protect the graft against destruction mediated by huPBL.
MATERIALS AND METHODS

Islet Isolation
Islet isolation via a modification of the automated procedure described by Ricordi et al. (29) , as well as islet culture and cryopreservation, has previously been described (12) . Three different islet preparations were used for this project.
Transfection
In each experiment, islets from the same preparation were divided into three separate groups. The first group was transfected with replication defective adenovirus 5 
Transplantation
Transplantation of islets under the renal capsule of NOD-scid mice was performed as described in a previ ous report (14) . Briefly, the mice were anesthetized, and a pocket was created under the right kidney capsule.
Three thousand islet equivalents were inserted into the pocket. Mice were transplanted with either islets treated with AdTNFi or islets treated with AdLacZ, or islets that had not been transfected. 
Human Islet Graft Function
Injection of huPBL
Destruction of human islet grafts by SEB activated human leukocytes was performed as described in previ ous work (14) . Briefly, human leukocytes were isolated from blood donor buffy coats and cultured for 36-48 h in RPMI medium containing 10% FBS and 1 pg/ml SEB. HLA-DR typing was conducted to ensure a double mismatch between leukocyte and islet donors. The leu kocytes were then washed three times with HBSS and injected IP into half of the mice. The other half of the mice received sham injections of the buffer from the last huPBL wash. 
X-gal Staining
CD45 Staining
Kidney and spleen sections were stained with an anti body to human CD45 using the ABC method described 
Data Analysis
Analysis of variance (ANOVA) was used evaluate whether there were differences in mean graft function among the TNFi, LacZ, and nontransfected groups that received huPBL as well as in those that did not. Onetailed r-tests were performed on the levels of human TNF-a.
RESULTS
Graft Function
Regardless of islet transfection status, there was no significant difference in graft function as measured by rioration 21 days after injection. In contrast, function of the grafts in both the LacZ huPBL and the nontransfec ted huPBL groups deteriorated significantly (Fig. 2 ).
X-gal Staining
At the conclusion of the experiment, sections of kid neys from the AdLacZ transfected mice were stained with X-gal. Kidneys from the other groups were used as controls. All sections from mice transfected with Ad-LacZ expressed the B-gal protein as evidenced by blue clusters in the grafts (Fig. 3 ) 36 days after transfection.
Tissue sections from mice transplanted with TNFi trans fected or nontransfected islets did not stain for B-gal (not shown).
Immunohistochemical Staining
Twenty kidneys removed 36 days after transplanta tion were immunostained with an insulin antibody. Sec tions from 13 kidneys stained positive for human insulin in islet-like structures located near mouse kidney tissue.
Insulin-staining grafts were not located in the remaining 7 kidneys (Table 1) . Graft retrieval and adequate histo logical sectioning proved to be a technical challenge.
This may have contributed to our inability to locate insu lin-staining structures in tissue from some mice that had significant amounts of human insulin detected in their serum.
The kidneys and spleens from the 20 mice were stained with an antibody to human CD45, a common leukocyte marker. We are currently attempting to deter mine which specific subsets of leukocytes infiltrate the grafts as well as their temporal sequence of invasion.
CD45 staining cells were found in grafts of all mice injected with huPBL if the graft could be located. Stain for CD45 was negative in tissue of the mice not receiv ing huPBL.
Stain results and graft function for the 20 mice are summarized in Table 1 . In 8 of the 10 huPBL-injected mice, CD45 staining cells were found either in spleen or in the islet graft. In the remaining two mice, evidence of successful huPBL engraftment was indirect (i.e., insu lin production had deteriorated to less than 25% of pre-huPBL levels). None of the buffer-injected mice had CD45 staining in grafts or spleens. Figure 4 shows Events similar to the cytokine-induced destruction of beta cells that may occur in autoimmune type I DM may also be involved in early loss of graft function in islet transplantation (1) . A combination of cytokines exhibit ing a synergistic effect could contribute to graft non function and destruction of islet grafts. In particular, TNF-a in combination with IL-1 and IFN appear to neg atively affect beta cell function and could play a part in islet graft destructive processes (1, 9, 22, 27) . Even isologous islets may be subject to cytokine-induced damage because injection of a soluble TNF receptor has been shown to decrease beta cell destruction in C57BL/6 mice transplanted with isologous islets (11) .
We used our NOD-scid model to determine whether local production of a TNF inhibitor via transfection of islets with AdTNFi could protect human islet grafts Received  Graft  Graft  Spleen  Graft  Mouse  huPBL  Islet  Stain  Stain  Stain  Function  ID  Injection  Transfection  Insulin  CD45  CD45 also apparent, because serum levels of human TNF in mice with TNFi transfected grafts were lower than in those mice carrying LacZ transfected or nontransfected grafts.
Previous islet transplant research has demonstrated that results from animal models cannot always be dupli cated in humans (28, 34) . It is well known that there are species differences in cytokine sensitivities and re sponses of both islets and leukocytes (10, 19, 32) . Our ability to prevent human leukocyte-mediated human is let graft destruction by the local production of an inhibi tor of the proinflammatory cytokine TNF-a suggests that inflammation and or cytokine toxicity is an essential part of human islet destruction in our model. The very rapid nature of most clinical islet graft failures, as well as the fact that the most successful human islet trans plant protocols have included antioxidative and anti-in flammatory procedures (17) , indicate that inflammation and inflammatory cytokines are also of importance for graft destruction in human recipients of human islets.
This raises the possibility that local expression of an in hibitor of the proinflammatory cytokine TNF-a may also prevent graft failure in clinical islet transplantation.
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